Vyant Bio
Rutherford
About Vyant Bio
Vyant Bio, Inc. (“Vyant Bio” or “Company”) operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The Company is executing on the integration of these two leading businesses to integrate human-powered scientific and technology-based systems and expertise with years of preclinical experience to de-risk and accelerate discovery and development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the Company.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $48.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2021)
- Ticker: nasdaq:VYNT
- Website: vyantbio.com
- Phone: +112015289200
Industries & Categories
Biotechnology, Genetics, Health Care, Health Diagnostics, Oncology
Social Profiles
Canonical: https://fsome.com/organization/vyant-bio-190134 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.